Adverum Biotechnologies announced the appointments of Dr. Rabia Gurses Ozden to the Company’s executive leadership team as chief medical officer, CMO, and Dr. Szilard Kiss to the Company’s Board of Directors. Dr. Ozden has stepped down from the Company’s Board of Directors, with Dr. Kiss filling the existing Board seat. Rabia Gurses Ozden most recently served as Chief Medical Officer for Ocular Therapeutix (OCUL). Szilard Kiss, M.D. brings over 20 years of ocular gene therapy experience and is a renowned medical and surgical vitreoretinal specialist.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADVM:
- Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Member of the Board of Directors
- Adverum Biotechnologies reports Q1 EPS ($1.50), consensus ($1.40)
- Adverum Biotechnologies to Participate in Upcoming May Investor Conferences
- Adverum Biotechnologies initiated with a Buy at H.C. Wainwright
- Adverum Biotechnologies management to meet with Truist
Questions or Comments about the article? Write to editor@tipranks.com